SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABSK061, a highly...
Hence then, the article about abbisko therapeutics fgfr2 3 inhibitor absk061 receives fda ind clearance for achondroplasia in children was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children )
Also on site :
- Lisa Kudrow Gets Brutally Honest About ‘Friends’ Fame
- 2000s Heavy Metal Rocker Makes $1.5 Million Move Before 2026 Tour
- Iran strikes fully loaded Kuwaiti oil tanker at Dubai port; spill risk flagged